Stock listing

NASDAQ:ELTX Elicio Therapeutics, Inc. Stock

Home listing (NASDAQ) of Elicio Therapeutics, Inc.

Follow Elicio Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ELTX

$1.45 USD -0.14 (-8.8%)

Close on Nov 20, 2026

Past year -81.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.44 – $1.59 USDNov 20, 2026
Volume
231,624 sharesNov 20, 2026
Market cap
$41.05M USDAt the close on Nov 20, 2026 · price × 28.31M shares outstanding
52-week range
$1.25 – $16.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$631,965 USDMedian day 309,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Elicio Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ELTX · Home$1.45 USD-0.14 (-8.8%)231,624$1.47$1.59$1.44$1.59Close on Nov 20, 2026
Frankfurt:9HA€1.25 EUR-0.17 (-12.0%)—€1.35€1.35€1.25€1.42Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ELTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.45-0.14-8.8%$1.47$1.59$1.44231,624
$1.59+0.16+11.2%$1.44$1.59$1.38549,610
$1.43-0.05-3.4%$1.48$1.54$1.37449,195
$1.48-0.02-1.3%$1.48$1.55$1.43209,497
$1.50-0.06-3.8%$1.57$1.60$1.48327,022
$1.56-0.07-4.3%$1.59$1.645$1.55232,784
$1.63+0.02+1.2%$1.61$1.665$1.53357,213
$1.61-0.035-2.1%$1.69$1.77$1.58197,081
$1.645+0.135+8.9%$1.49$1.74$1.48219,011
$1.51+0.11+7.9%$1.40$1.52$1.25756,112
$1.40-0.16-10.3%$1.58$1.66$1.40281,686
$1.56+0.04+2.6%$1.58$1.64$1.48289,096
$1.52-0.07-4.4%$1.71$1.73$1.445516,878
$1.59-0.09-5.4%$1.75$1.80$1.535330,706
$1.68-0.07-4.0%$1.74$1.78$1.655183,462
$1.75-0.10-5.4%$1.82$1.89$1.745135,951
$1.85+0.02+1.1%$1.80$1.89$1.72216,925
$1.83+0.13+7.6%$1.67$1.835$1.655342,266
$1.70-0.20-10.5%$1.91$1.943$1.64422,974
$1.90-0.04-2.1%$1.94$1.98$1.79464,082
$1.94+0.27+16.2%$1.68$1.97$1.67515,800
$1.67+0.10+6.4%$1.57$1.68$1.52269,900
$1.57+0.02+1.3%$1.52$1.62$1.50275,800
$1.55-0.01-0.6%$1.57$1.595$1.44298,100
$1.56-0.22-12.4%$1.81$1.85$1.55333,400
$1.78-0.01-0.6%$1.78$1.86$1.763169,400
$1.79+0.02+1.1%$1.77$1.91$1.75373,300
$1.77-0.11-5.9%$1.88$1.88$1.73232,000
$1.88-0.01-0.5%$1.90$1.91$1.82164,400
$1.89+0.08+4.4%$1.83$1.92$1.785306,200
$1.81-0.04-2.2%$1.85$1.85$1.74267,000
$1.85-0.03-1.6%$1.87$1.92$1.83138,900
$1.88-0.04-2.1%$1.90$1.96$1.86259,100
$1.920.000.0%$1.93$1.96$1.81200,200
$1.920.000.0%$1.95$1.97$1.85175,900
$1.92+0.10+5.5%$1.82$1.96$1.82310,200
$1.82-0.02-1.1%$1.86$1.86$1.78274,000
$1.84-0.01-0.5%$1.85$1.90$1.77452,500
$1.85+0.01+0.5%$1.85$1.90$1.81222,100
$1.84-0.04-2.1%$1.88$1.90$1.82165,400
$1.88+0.01+0.5%$1.88$2.00$1.81339,700
$1.870.000.0%$1.87$1.895$1.84195,400
$1.87-0.04-2.1%$1.92$1.925$1.82402,600
$1.91+0.02+1.1%$1.92$2.02$1.91483,600
$1.89+0.025+1.3%$1.86$2.00$1.86689,700
$1.865+0.095+5.4%$1.79$1.90$1.785340,200
$1.77-0.22-11.1%$1.90$1.90$1.705629,200
$1.99-0.01-0.5%$2.01$2.02$1.915319,000
$2.00-0.05-2.4%$2.06$2.09$1.95391,700
$2.05-0.06-2.8%$2.14$2.20$2.02445,600
$2.11-0.07-3.2%$2.17$2.20$2.07343,100
$2.18-0.17-7.2%$2.37$2.375$2.17457,400
$2.35-0.06-2.5%$2.42$2.46$2.34324,600
$2.41-0.09-3.6%$2.50$2.50$2.36487,900
$2.50-0.05-2.0%$2.55$2.56$2.465272,700
$2.55-0.01-0.4%$2.57$2.61$2.48397,600
$2.56-0.14-5.2%$2.70$2.71$2.55334,300
$2.70-0.14-4.9%$2.84$2.87$2.70412,200
$2.84-0.16-5.3%$3.00$3.00$2.84421,600
$3.00+0.02+0.7%$3.00$3.05$2.97131,200
$2.98-0.03-1.0%$3.00$3.07$2.96181,900
$3.01+0.03+1.0%$3.00$3.095$2.98223,600
$2.98-0.06-2.0%$3.06$3.06$2.94309,000
$3.04-0.035-1.1%$3.11$3.11$3.03279,200
$3.075-0.055-1.8%$3.11$3.135$3.02207,800

Splits

1 split · NASDAQ:ELTX · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
NASDAQ:ELTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Elicio Therapeutics, Inc. news

Elicio Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 36 in all · newest Nov 5, 2026 · oldest 2025
Decks
15 decks · latest September 2026

Where Elicio Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ELTX · Home listing · This pageNASDAQUnited StatesUSD
LS Exchange:A3CY4JLS ExchangeGermanyEUR
BOATS:ELTXBOATSUnited StatesUSD
Lang & Schwarz:A3CY4JLang & SchwarzGermanyEUR
gettex:9HAgettexGermanyEUR
Dusseldorf:9HADusseldorfGermanyEUR
Frankfurt:9HAFrankfurtGermanyEUR
Munich:9HAMunichGermanyEUR
Tradegate:9HATradegateGermanyEUR

Valuation

Price/book 2.2× against a median of 2.8×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$19.78M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.5×
Beta vs S&P 500
1.81

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Elicio Therapeutics, Inc. · NASDAQ:ELTXUS$41.05MUS$19.78Mn/an/an/a2.2×n/a0.5×1.81
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBPUS$42.45M−US$68.98Mn/an/an/a0.5×n/a0.1×1.85
Arecor Therapeutics PLC · LSE:ARECUS$42.37MUS$38.32M48.8×17.1×n/a8.8×38.7%0.0×n/a
OS Therapies Incorporated · AMEX:OSTXUS$42.00MUS$41.57Mn/an/an/an/an/an/a1.70
Advagene Biopharma Co., Ltd. · TPEX:6709US$41.89MUS$32.03Mn/an/an/a3.9×n/a0.0×n/a
Biomea Fusion, Inc. · NASDAQ:BMEAUS$41.75MUS$15.85Mn/an/an/a5.5×n/a0.1×1.14
Prescient Therapeutics Limited · ASX:PTXUS$41.64MUS$35.80Mn/an/an/a4.4×n/a0.0×n/a
Mereo BioPharma Group plc · NASDAQ:MREOUS$41.52MUS$16.00Mn/a20.0×n/a1.8×n/a0.0×1.34
MiNK Therapeutics, Inc. · NASDAQ:INKTUS$40.93MUS$33.46Mn/a167×n/an/an/an/a0.81
Dogwood Therapeutics, Inc. · NASDAQ:DWTXUS$39.57MUS$34.74Mn/a347×n/a0.6×n/a0.0×0.79
Median of the othersUS$41.82MUS$32.74M48.8×93.6×2.8×38.7%0.0×1.24

Forecasts

2 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
13.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.63 · 4 analysts

Team and board

Officers

OfficerRole
Robert ConnellyChief Executive Officer
Megan FiloonGeneral Counsel, Secretary and Compliance Officer
Christopher HaqqExecutive Vice President, Head of Research and Development and Chief Medical Officer
Esther WelkowskySenior Vice President, Clinical Development
Joy SeymourSenior Vice President, Head of Regulatory Affairs
Marc WolfgangChief Technology Officer
Peter DeMuthChief Scientific Officer
Preetam ShahChief Strategy and Financial Officer

Board

DirectorRole
Julian AdamsChairman
Allen R. NissensonDirector
Carol AsheDirector
Jay VenkatesanDirector
Karen J. WilsonDirector
Robert ConnellyChief Executive Officer
Robert R. RuffoloDirector
Yekaterina ChudnovskyDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+7.9%
Q2 2026Aug 13, 2026 · After close−1.9%
Q1 2026May 11, 2026 · After close−9.1%
Q3 2025Nov 13, 2025 · After close−2.2%
Q2 2025Aug 7, 2025 · After close+1.4%
Q1 2025May 13, 2025 · After close−5.3%
Q4 2024Mar 27, 2025 · Before open−4.1%
Q3 2024Nov 13, 2024 · After close+4.8%
Q2 2024Aug 13, 2024 · After close−5.3%
Q1 2024May 15, 2024 · After close−9.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 29, 2024 · Before open−6.3%
Q3 2023Nov 9, 2023 · After close−0.3%
Q2 2023Aug 11, 2023 · Before open0.0%
Q1 2023May 10, 2023 · After close−6.0%
Q4 2022Mar 29, 2023+12.5%
Q3 2022Nov 14, 2022−12.3%
Q2 2022Aug 16, 2022−1.9%
Q1 2022May 17, 2022−15.4%
Quarter to Sep 30, 2021Nov 12, 2021−5.6%
Quarter to Jun 30, 2021Jul 13, 2021−7.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck31 slidesSeptember 2026
Technical Presentation (June 2026)Technical23 slidesJun 24, 2026
Corporate Update (June 2026)Corporate update16 slidesJun 15, 2026
Investor Presentation (January 2026)Investor deck50 slidesJanuary 2026
Technical Presentation (September 2025)Technical12 slidesSep 17, 2025
Investor Presentation (August 2025)Investor deck46 slidesAugust 2025
Investor Presentation (May 2025)Investor deck52 slidesMay 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 23, 2025
Investor Presentation (December 2024)Investor deck32 slidesDec 12, 2024
Investor Presentation (June 2024)Investor deck40 slidesJune 2024
All 15 decks
DeckKindSlidesDate
Investor Presentation (January 2024)Investor deck24 slidesJanuary 2024
Technical Presentation (December 2023)Technical17 slidesDec 1, 2023
Investor Presentation (September 2023)Investor deck25 slidesSep 28, 2023
Investor Presentation (June 2023)Investor deck21 slidesJune 2023
Angion Biomedica — Merger or Acquisition (January 2023)Merger or acquisition22 slidesJan 18, 2023

Open Decks

Financings

RaiseDate
Registered direct offering of shares of common stock
Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1
Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.
Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline
Aug 13, 2026
Registered direct offering of common stock
Announced: about US$15M · Titan Partners, a division of American Capital Partners +1
Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.
Use of proceeds: Fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, the pipeline and platform, working capital and general corporate purposes
Jul 2, 2026
At-the-market programme of shares under at-the-market program
Tranche closed: US$11.1M raised
Nov 13, 2025
Senior secured promissory note with warrants
Closed: US$10M raised · Warrants at US$7.75 for 60 months
Buyers: GKCC, LLC (existing investor; $10 million senior secured promissory note and warrants to purchase 103,225 shares)
Use of proceeds: With existing cash, to support operations into Q1 2026, beyond the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025
Jun 4, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Angion Biomedica Corp. Priced at US$16.00 a share on Feb 4, 2021.

Price
US$16.00 a share
Shares offered
5,000,000 shares of common stock
Offering size
US$80 million
Underwriters' option
Up to 750,000 more shares
Listing
ANGN on the Nasdaq Global Select Market
Underwriters
Cowen, Stifel, H.C. Wainwright & Co., Oppenheimer & Co. · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 14, 2020
Filed publiclyJan 15, 2021
Amended twiceNewest Feb 4, 2021
Shares registered with an exchangeFeb 2, 2021
Declared effective by the SECFeb 4, 2021
Final prospectus, with the priceFeb 5, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Feb 5, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Revenue0002.30M28.3M2.88M1.49M4.03M6.58M7.30M
Cost of revenue1.13M1.18M1.17M0433.0K1.19M1.14M380.0K3.17M3.67M
Gross profit-1.13M-1.18M-1.17M-1.06M27.1M1.06M351.0K3.65M3.41M3.62M
Research and development24.9M33.7M23.8M18.1M48.7M39.0M29.8M9.15M196.0K
Selling, general and administrative12.8M11.3M11.9M5.63M7.54M3.00M2.80M
Operating income-37.7M-45.0M-35.7M-23.7M-39.3M-55.3M-38.6M-14.3M-397.8K-419.2K
Depreciation and amortization204.0K321.0K382.0K390.0K91.0K98.0K496.0K2.00K460.3K463.2K
EBITDA-37.5M-44.7M-35.4M-23.3M-39.2M-55.2M-38.1M-14.3M62.5K44.0K
Interest expense1.13M455.0K1.06M3.60M876.4K8.85M300.4K307.4K
Income before tax-39.6M-51.9M-35.2M-38.8M-54.6M-80.1M-40.7M-20.0M1.73M1.19M
Income tax00000081.5K452.8K201.9K
Net income-39.6M-51.9M-35.2M-28.2M-54.6M-80.1M-40.7M-20.0M632.2K307.3K
Earnings per share, basic-2.58-4.25-6.96-89.27-1.93-5.43-4.99-6.79103.3150.21
Earnings per share, diluted-2.58-4.25-6.96-89.27-1.93-5.43

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Cash and equivalents18.6M17.6M12.9M6.16M88.8M34.6M5.57M25.5M2.06M1.40M
Receivables0806.0K5.00M440.0K107.0K485.8K580.4K
Inventory4.22M189.0K-4.62M-63.7K1
Current assets19.3M20.7M16.3M10.7M91.2M42.3M6.11M25.7M2.62M2.06M
Property, plant and equipment295.0K483.0K717.0K1.15M451.0K156.0K1.43M
Total assets25.9M28.2M27.1M22.7M96.5M47.3M11.9M26.6M11.1M11.0M
Accounts payable672.0K1.04M4.37M2.81M4.71M5.58M11.2M534.0K37.6K209.5K
Current liabilities8.11M11.5M9.76M6.87M11.3M107.4M26.6M7.36M1.15M1.10M
Long-term debt9.41M20.0M0635.0K
Total debt10.0M20.0M6.92M7.48M0635.0K10.8M5.32M5.44M
Total liabilities24.2M39.5M15.8M13.7M15.0M137.8M30.5M7.72M6.60M6.79M
Shareholders' equity1.64M-11.3M11.4M-102.1M-74.5M-90.4M-18.6M18.9M2.34M1.71M
Shares outstanding17.8M11.0M9.60M320.3K30.0M15.3M8.15M2.95M6.12K6.12K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2013FY2012
Cash from operations-37.0M-37.1M-32.7M-22.2M-52.6M-22.9M-24.6M-8.02M1.89M1.07M
Capital spending-16.0K-87.0K-66.0K-654.0K-382.0K-41.0K-242.0K0-17.6K-47.7K
Free cash flow-37.0M-37.2M-32.8M-22.8M-53.0M-22.9M-24.8M-8.02M1.87M1.02M
Cash from investing-16.0K-84.0K-32.0K-654.0K-382.0K-41.0K-242.0K-67.6K-47.7K
Cash from financing36.7M42.3M38.6M21.2M107.2M52.4M4.89M31.7M-1.17M-429.2K
Share buybacks-549.0K-150.0K0-36.0K-375.0K
Change in cash-225.0K5.19M5.89M-1.63M54.1M29.0M-19.9M23.5M652.8K588.2K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026Meeting outcomeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
DEF 14A · Proxy statementOct 9, 2026Meeting noticeSEC
8-K · Current reportSep 14, 2026Current reportSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
424B5 · ProspectusJul 2, 2026Offer documentSEC
8-K · Current reportJul 2, 2026Material contractSEC
8-K · Current reportJun 24, 2026Current reportSEC
8-K · Current reportJun 17, 2026Current reportSEC
8-K · Current reportJun 15, 2026Current reportSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
10-K/A · Annual report, amendedApr 29, 2026Annual reportSEC
EFFECT · Notice that a registration is effectiveMar 17, 2026Other filingsSEC
8-K · Current reportMar 16, 2026Material contractSEC
424B5 · ProspectusMar 16, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
CORRESP · Letter to the SECMar 12, 2026Other filingsSEC
S-3/A · Registration statement, amendedMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
UPLOAD · Letter from the SECMar 6, 2026Other filingsSEC
S-3/A · Registration statement, amendedMar 2, 2026Offer documentSEC
S-3 · Registration statementFeb 27, 2026Offer documentSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 4, 2025Other filingsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
S-3 · Registration statementNov 13, 2025Offer documentSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2025Big-stake noticeSEC
8-K · Current reportSep 17, 2025Current reportSEC
8-K · Current reportAug 12, 2025Current reportSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportAug 5, 2025Current reportSEC
4 · Change in ownershipJun 4, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 4, 2025Big-stake noticeSEC
8-K · Current reportJun 4, 2025Material contractSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
8-K · Current reportMay 20, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 9, 2025Annual reportSEC
DEF 14A · Proxy statementApr 9, 2025Meeting noticeSEC
3 · Initial statement of ownershipApr 2, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 31, 2025Offer documentSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportMar 24, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
8-K · Current reportMar 5, 2025FinancingSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 30, 2025Material contractSEC
424B5 · ProspectusJan 30, 2025Offer documentSEC
8-K · Current reportJan 23, 2025Current reportSEC
8-K · Current reportJan 22, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 7, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedJan 2, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
8-K · Current reportDec 12, 2024Current reportSEC
8-K · Current reportDec 3, 2024Current reportSEC
4 · Change in ownershipNov 29, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
424B3 · ProspectusNov 22, 2024Offer documentSEC
8-K · Current reportNov 21, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveNov 21, 2024Other filingsSEC
CORRESP · Letter to the SECNov 18, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 15, 2024Other filingsSEC
S-3 · Registration statementNov 13, 2024Offer documentSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
8-K · Current reportNov 7, 2024Current reportSEC
8-K · Current reportNov 7, 2024Current reportSEC
8-K · Current reportOct 17, 2024Management or board changeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
ARS · Annual report to shareholdersSep 27, 2024Annual reportSEC
DEF 14A · Proxy statementSep 27, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 17, 2024Meeting noticeSEC
8-K · Current reportAug 30, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportAug 12, 2024Material contractSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 2, 2024Big-stake noticeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
424B5 · ProspectusJun 28, 2024Offer documentSEC
8-K · Current reportJun 28, 2024Material contractSEC
424B5 · ProspectusJun 27, 2024Offer documentSEC
8-K · Current reportJun 27, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJun 12, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveJun 12, 2024Other filingsSEC
CORRESP · Letter to the SECJun 10, 2024Other filingsSEC
CORRESP · Letter to the SECJun 7, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 6, 2024Other filingsSEC
S-3 · Registration statementJun 3, 2024Offer documentSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
S-3/A · Registration statement, amendedJun 3, 2024Offer documentSEC
8-K · Current reportMay 23, 2024Current reportSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
8-K · Current reportMay 15, 2024ResultsSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
SC 13D/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECApr 10, 2024Other filingsSEC
8-K · Current reportApr 5, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 29, 2024Offer documentSEC
S-3 · Registration statementMar 29, 2024Offer documentSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
8-K · Current reportMar 29, 2024ResultsSEC
DMar 28, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedMar 20, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMar 20, 2024Big-stake noticeSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
8-K · Current reportMar 18, 2024Material contractSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 5, 2024Insider tradeSEC
8-K · Current reportFeb 2, 2024Management or board changeSEC
8-K · Current reportJan 17, 2024Current reportSEC
8-K · Current reportJan 16, 2024Current reportSEC
8-K · Current reportJan 9, 2024Current reportSEC
DJan 5, 2024Other filingsSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 27, 2023Big-stake noticeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedDec 26, 2023Big-stake noticeSEC
8-K · Current reportDec 22, 2023Material contractSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportNov 3, 2023Current reportSEC
8-K · Current reportOct 20, 2023Management or board changeSEC
8-K · Current reportOct 12, 2023Management or board changeSEC
8-K · Current reportSep 27, 2023Current reportSEC
8-K · Current reportSep 7, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedAug 30, 2023Big-stake noticeSEC
8-K · Current reportAug 30, 2023Management or board changeSEC
S-8 · Registration statement for employee plansAug 21, 2023Offer documentSEC
8-K/A · Current report, amendedAug 11, 2023Current reportSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 11, 2023ResultsSEC
SC 13G/A · Big-stake notice, amendedJul 7, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJun 14, 2023Big-stake noticeSEC
SC 13D · Big-stake noticeJun 14, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJun 12, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 12, 2023Insider tradeSEC
SC 13D · Big-stake noticeJun 12, 2023Big-stake noticeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC
3 · Initial statement of ownershipJun 7, 2023Insider tradeSEC

This page holds 200 of 385 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Elicio Therapeutics, Inc.’s releases · as of Nov 3, 2026

Common shares
28,307,225
Fully diluted
28,307,225

Fully diluted

LineSharesAs of
Common shares28,307,225Nov 3, 2026

Warrants and options

Lot
Warrants · US$7.75 · expire about Jun 2030

Share count over time

CountShares
Nov 3, 202628,307,225

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Shah Capital Management1.25M4.4%US$2.27MSep 30, 2026
Knoll Capital Management, LLC1.21M4.3%US$2.21MSep 30, 2026
Vanguard790K2.8%US$1.44MSep 30, 2026
BlackRock740K2.6%US$1.35MSep 30, 2026
Citadel543K1.9%US$989KSep 30, 2026
AQR Capital Management LLC449K1.6%US$817KSep 30, 2026
Geode Capital414K1.5%US$754KSep 30, 2026
Morgan Stanley396K1.4%US$720KSep 30, 2026
UBS236K0.83%US$430KSep 30, 2026
State Street232K0.82%US$423KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Renaissance Technologies161K0.57%US$292KSep 30, 2026
Northern Trust132K0.47%US$240KSep 30, 2026
AllianceBernstein81,2800.29%US$148KSep 30, 2026
Goldman Sachs56,6770.20%US$103KSep 30, 2026
Susquehanna54,4860.19%US$99,165Sep 30, 2026
Nuveen45,1210.16%US$82,120Sep 30, 2026
Schwab31,7060.11%US$57,705Sep 30, 2026
Quadrature Capital Ltd30,9360.11%US$56,304Sep 30, 2026
Ieq Capital, LLC25,8140.09%US$46,981Sep 30, 2026
HB Wealth Management, LLC25,1180.09%US$45,715Sep 30, 2026
Leonteq Securities AG20,0000.07%US$36,400Sep 30, 2026
XTX Topco Ltd19,9650.07%US$36,336Sep 30, 2026
Marshall Wace, LLP19,6710.07%US$35,801Sep 30, 2026
HighTower Advisors, LLC18,6290.07%US$33,905Sep 30, 2026
Fidelity17,8070.06%US$32,409Sep 30, 2026
Mercer Global Advisors Inc16,3430.06%US$29,745Sep 30, 2026
Mariner, LLC16,2840.06%US$29,638Sep 30, 2026
BNY15,8840.06%US$28,909Sep 30, 2026
Bank of America15,6240.06%US$28,436Sep 30, 2026
Rhumbline Advisers14,7920.05%US$26,916Sep 30, 2026
Millennium14,3850.05%US$26,181Sep 30, 2026
New York State Common Retirement Fund14,2000.05%US$25,844Sep 30, 2026
Meyer Handelman Co13,8990.05%US$25,296Sep 30, 2026
Wealth Enhancement Advisory Services, LLC12,5520.04%US$22,719Sep 30, 2026
Squarepoint Ops LLC12,4570.04%US$22,672Sep 30, 2026
DWS11,0160.04%US$20,049Sep 30, 2026
Creative Planning10,6060.04%US$19,303Sep 30, 2026
T. Rowe Price10,5860.04%US$20,000Sep 30, 2026
Abel Hall, LLC10,1780.04%US$18,524Sep 30, 2026
Mayflower Financial Advisors, LLC10,0000.04%US$18,200Sep 30, 2026
&Partners10,0000.04%US$18,200Sep 30, 2026
Moody Lynn Lieberson & Walker, LLC10,0000.04%US$18,200Sep 30, 2026
Diadema Partners LP9,4400.03%US$17,181Sep 30, 2026
Global Retirement Partners, LLC9,2110.03%US$16,764Sep 30, 2026
JPMorgan7,6800.03%US$14,131Sep 30, 2026
BNP Paribas6,7860.02%US$12,351Sep 30, 2026
Barclays6,7550.02%US$12,294Sep 30, 2026
CaixaBank, S.A.6,6000.02%US$12,012Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.6,3130.02%US$11,490Sep 30, 2026
Group One Trading LLC5,0060.02%US$9,111Sep 30, 2026

This page holds 50 of 77 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund415K1.5%US$1.62MJun 30, 2026
iShares Russell 2000 ETF319K1.1%US$1.25MJun 30, 2026
Vanguard Extended Market Index Fund144K0.51%US$561KJun 30, 2026
Fidelity Small Cap Index Fund140K0.49%US$391KJul 31, 2026
iShares Russell 2000 Growth ETF122K0.43%US$476KJun 30, 2026
Fidelity Extended Market Index Fund58,4340.21%US$668KMay 31, 2026
iShares Micro-Cap ETF43,7170.15%US$171KJun 30, 2026
EQ/Small Company Index Portfolio40,6400.14%US$159KJun 30, 2026
EQ/AB Small Cap Growth Portfolio40,6400.14%US$159KJun 30, 2026
Schwab Small-Cap Index Fund31,7060.11%US$88,777Jul 31, 2026
All 48 holders
HolderSharesOf the companyValueAs of
Master Small Cap Index Series29,4340.10%US$115KJun 30, 2026
Fidelity Total Market Index Fund21,2890.08%US$244KMay 31, 2026
Nuveen Small Cap Blend Index Fund17,8880.06%US$50,086Jul 31, 2026
Fidelity Series Total Market Index Fund16,6170.06%US$190KMay 31, 2026
EQ/2000 Managed Volatility Portfolio16,4490.06%US$64,316Jun 30, 2026
Fidelity Small Cap Growth Index Fund12,2960.04%US$48,077Jun 30, 2026
Fidelity Nasdaq Composite Index Fund11,9280.04%US$136KMay 31, 2026
Small Cap Core Fund10,0860.04%US$39,436Jun 30, 2026
Small Cap Index Fund6,7440.02%US$26,369Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund6,5790.02%US$25,724Jun 30, 2026
Vanguard Balanced Index Fund6,5750.02%US$25,708Jun 30, 2026
Small-Cap Index Portfolio6,5250.02%US$25,513Jun 30, 2026
Global X Russell 2000 ETF6,2020.02%US$17,366Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio3,5000.01%US$13,685Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio3,3630.01%US$13,149Jun 30, 2026
NVIT Small Cap Index Fund3,3510.01%US$13,102Jun 30, 2026
BlackRock Small Cap Index V.I. Fund3,0630.01%US$11,976Jun 30, 2026
1290 VT Micro Cap Portfolio2,9300.01%US$11,456Jun 30, 2026
Nationwide Small Cap Index Fund2,009<0.01%US$5,625Jul 31, 2026
DWS Small Cap Index VIP1,989<0.01%US$7,777Jun 30, 2026
T. Rowe Price Small-Cap Index Fund1,952<0.01%US$7,632Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio1,822<0.01%US$7,124Jun 30, 2026
SA Small Cap Index Portfolio1,777<0.01%US$4,976Jul 31, 2026
Victory Extended Market Index Fund1,494<0.01%US$4,183Jul 31, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio1,328<0.01%US$5,192Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio1,176<0.01%US$4,598Jun 30, 2026
PD Small-Cap Growth Index Portfolio1,089<0.01%US$4,258Jun 30, 2026
Venerable Small Cap Index Fund1,033<0.01%US$4,039Jun 30, 2026
SmallCap Growth Fund I991<0.01%US$2,775Jul 31, 2026
Total Stock Market Index Trust374<0.01%US$1,462Jun 30, 2026
Ultra Small Cap Profund167<0.01%US$468Jul 31, 2026
Russell 2000 2x Strategy Fund70<0.01%US$274Jun 30, 2026
Profund Vp Ultra Small Cap53<0.01%US$207Jun 30, 2026
Profund Vp Small Cap35<0.01%US$137Jun 30, 2026
Russell 2000 Fund32<0.01%US$125Jun 30, 2026
Russell 2000 1.5x Strategy Fund19<0.01%US$74Jun 30, 2026
Small-Cap Profund11<0.01%US$31Jul 31, 2026
Russell 2000(R) 1.5x Strategy Fund4<0.01%US$16Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Yekaterina Chudnovsky48.10%9.66MMar 5, 2025Schedule 13D
GKCC, LLC48.00%9.75MJun 3, 2025Schedule 13D
Moti Investments LLC6.10%1.41MJul 1, 2026Schedule 13G
Knoll Capital Management, LLC5.30%1.21MJul 1, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Karen J. Wilson
Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Serina Therapeutics, Inc. (Director · Since at least Jan 14, 2025); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vaxart, Inc. (Director · Aug 25, 2020 – Jun 16, 2021 · Past); Jazz Pharmaceuticals plc (SVP, Finance & PAO · Mar 9, 2011 – Mar 5, 2019 · Past)
Director · Since at least Feb 4, 2021
Brian Piekos
Other companies: KalVista Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Sep 9, 2024); Disc Medicine, Inc. (CFO · Feb 12, 2021 – May 31, 2022 · Past); AMAG Pharmaceuticals Inc (Chief Financial Officer · Jun 9, 2020 – Nov 16, 2020 · Past)
Chief Financial Officer · Jun 1, 2023 – Feb 1, 2024 · Past
Jennifer J. Rhodes
Other companies: ACADIA Pharmaceuticals Inc. (Chief Legal Officer and Secretary · Since at least Feb 6, 2024); Adamas Pharmaceuticals Inc (CBO, GC & Compliance Officer · Apr 11, 2016 – Jun 20, 2019 · Past); Medivation Inc (GC & Corporate Secretary · Mar 26, 2013 – Mar 16, 2015 · Past)
See Remarks · Feb 4, 2021 – Mar 2, 2022 · Past
Christopher Haqq
Other companies: Surrozen, Inc. (Director · Nov 18, 2020 – Nov 18, 2020 · Past); Atara Biotherapeutics, Inc. (EVP, R&D & Chief Scientific Of · Oct 15, 2014 – Feb 15, 2019 · Past)
Executive Vice President, Head of Research and Development and Chief Medical Officer · Since at least Jun 1, 2023
Gilbert S. Omenn
Other companies: Amesite Inc. (Director · Since at least Sep 25, 2020); Galectin Therapeutics Inc. (Director · Since at least Dec 14, 2017)
Director · Feb 4, 2021 – Jun 9, 2022 · Past
Jay Venkatesan
Other companies: Serina Therapeutics, Inc. (Director · Since at least Feb 12, 2025); Alpine Immune Sciences Inc (Director · Jul 15, 2022 – Jul 15, 2022 · Past)
Director · Since at least May 20, 2022
Julian Adams
Other companies: Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Palvella Therapeutics, Inc. (Director · Jul 25, 2016 – Jan 25, 2018 · Past)
Chairman · Since at least Jun 1, 2023
Victor F. Ganzi
Other companies: Aveanna Healthcare Holdings Inc. (Audit Committee Chair, Independent Director · Since at least Jun 30, 2022); Willis Towers Watson Public Limited Company (Director · May 11, 2022 – Jun 8, 2022 · Past)
Director · May 27, 2022 – Jun 9, 2022 · Past
Allen R. Nissenson
Other companies: Rockwell Medical, Inc. (Director · Since at least Dec 11, 2020)
Director · Since at least Feb 4, 2021
John F Neylan
Other companies: Keryx Biopharmaceuticals Inc (Chief Medical Officer · Apr 22, 2015 – Dec 12, 2018 · Past)
See Remarks · Feb 4, 2021 – Mar 2, 2022 · Past
All 21 people
PersonSeat
Carol AsheDirector · Since at least Nov 4, 2026
Esther WelkowskySenior Vice President, Clinical Development · Since at least Nov 5, 2026
Itzhak GoldbergDirector · Feb 4, 2021 – Jul 1, 2022 · Past
Joy SeymourSenior Vice President, Head of Regulatory Affairs · Since at least Nov 5, 2026
Marc WolfgangChief Technology Officer · Since at least Nov 19, 2025
Megan FiloonGeneral Counsel, Secretary and Compliance Officer · Since at least Nov 5, 2026
Peter DeMuthChief Scientific Officer · Since at least Jun 1, 2023
Preetam ShahChief Strategy and Financial Officer · Since at least Apr 30, 2026
Robert ConnellyChief Executive Officer · Since at least Jun 1, 2023
Robert R. RuffoloDirector · Since at least Nov 5, 2026
Yekaterina ChudnovskyDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Elicio Therapeutics, Inc.